AURORA, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG) dba Vitro Biopharma has received funding related to exercise of outstanding Class A warrants held by a group of three private investors. These funds will be used primarily to advance the Company’s stem cell technology for the production of human beta islets from stem cell lines that the Company has previously developed. An immediate goal is the commercialization of stem cell-derived human beta islets for applications in research, drug development and drug discovery. In addition, the terms of the agreement underlying this funding include expansion of the Board of Directors and efforts to increase shareholder equity through the reduction of corporate liabilities.
